baricitinib
Orphan DrugFDA Approved, EMA Approved
Description
Baricitinib is a selective JAK1/JAK2 inhibitor that modulates interferon signaling pathways. It has been investigated for use in type 1 interferonopathies due to its ability to reduce interferon-driven inflammation. The drug is approved for rheumatoid arthritis and has orphan designation for certain autoinflammatory conditions.
Indications & Therapeutic Use
type 1 interferonopathy, autoinflammatory syndromes
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
baricitinib
| Generic Name | baricitinib |
| Brands | 1 brand available |
| Active Ingredient | baricitinib |
| Drug Class | type 1 interferonopathy |
| Manufacturer | Eli Lilly and Company |
| Dosage Forms | oral tablet, 2mg, 4mg |
| Medical Code | L04AA37 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT03334396 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes